Miniaturization of a Lumit p-ERK immunoassay for cell-based high-throughput screening of a chemogenetic small-molecule library
SLAS Technology · 2026-09 · 40 · 100445
DOI: 10.1016/j.slast.2026.100445 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLAS Technology, 2026-09. Verfasst von Matthew Swiatnicki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Promega Corporation, 2800 Woods Hollow Rd, Madison, WI, 53711, USA. Electronic address: Matthew.Swiatnicki@promega.com. Hauptthemen laut MEDLINE: High-Throughput Screening Assays, Small Molecule Libraries, Miniaturization, Extracellular Signal-Regulated MAP Kinases. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cell-based assays that report endogenous signaling events are attractive for high-throughput screening (HTS), but many formats rely on engineered reporters or fluorescence detection that can be limited by background and compound interference. We adapted the bioluminescent Lumit p-ERK1 (T202) immunoassay to 384- and 1536-well plate formats suitable for HTS. Using MCF-7 cells stimulated with EGF or PMA, we optimized lysis conditions and antibody concentrations to maximize signal-to-background while preserving detection of basal p-ERK. In 384-well plates, a manually run screen of a 190-compound FDA-approved Tocris library yielded an average Z' factor of 0.69 and a ∼32-fold signal window and enriched for known MAPK/ERK pathway inhibitors. In 1536-well format, a single-concentration screen of ∼7000 chemogenetically annotated small molecules produced a Z' factor of 0.60, an ∼18-fold signal window, and hit rates of 3.4% for inhibitors and 1.3% for activators. Concentration-response testing confirmed 95% and 57% of these, respectively. Orthogonal p-ERK HTRF assays showed high concordance with the Lumit assay, and target annotation analysis revealed enrichment for MEK, ERK, BRAF, PKC. To support plate-based HTS campaigns such as the 1536-well screen of a chemogenetic compound library, we used an alternative substrate dilution buffer that markedly improves on-deck substrate stability for at least 18 h without altering EC₅₀/IC₅₀ values or assay window, enabling reliable integration of the Lumit p-ERK assay into automated HTS workflows. Together, these data support the use of the Lumit p-ERK assay as a scalable, automation-compatible bioluminescent format for cell-based assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Promega Corporation, 2800 Woods Hollow Rd, Madison, WI, 53711, USA. Electronic address: Matthew.Swiatnicki@promega.com.
- Novartis Biomedical Research, 181 Massachusetts Avenue, Cambridge, MA, 02139, USA.
- Promega Corporation, 2800 Woods Hollow Rd, Madison, WI, 53711, USA. Electronic address: hicham.zegzouti@promega.com.
Zitieren
APA
Swiatnicki, M., Cho, H. H., Auld, D., & Zegzouti, H. (2026). Miniaturization of a Lumit p-ERK immunoassay for cell-based high-throughput screening of a chemogenetic small-molecule library. SLAS Technology, 40, 100445. https://doi.org/10.1016/j.slast.2026.100445
Vancouver
Swiatnicki M, Cho HH, Auld D, Zegzouti H. Miniaturization of a Lumit p-ERK immunoassay for cell-based high-throughput screening of a chemogenetic small-molecule library. SLAS Technology. 2026;40:100445. doi:10.1016/j.slast.2026.100445
BibTeX
@article{Swiatnicki2026,
author = {Swiatnicki, Matthew and Cho, Hyun-Hee and Auld, Douglas and Zegzouti, Hicham},
title = {Miniaturization of a Lumit p-ERK immunoassay for cell-based high-throughput screening of a chemogenetic small-molecule library},
journal = {SLAS Technology},
year = {2026},
volume = {40},
pages = {100445},
doi = {10.1016/j.slast.2026.100445}
}
EUVIMED